Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1062380 | 0.78 | — | — | |
| SCHEMBL14414058 | 0.78 | USP2 (0.42) | — | |
| SCHEMBL7705221 | 0.78 | USP2 (0.42) | — | |
| SCHEMBL11027256 | 0.72 | — | — | |
| SCHEMBL18367814 | 0.71 | KDM4E (0.36) | — | |
| SCHEMBL6282115 | 0.71 | KDM4E (0.36) | — | |
| Acetic Acid SCHEMBL2479619 | 0.69 | SLC1A3 (0.35) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL17674869 | 0.69 | KDM4E (0.34) | — | |
| SCHEMBL20855695 | 0.69 | KDM4E (0.34) | — | |
| SCHEMBL11160927 | 0.69 | KDM4E (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2147920-B1 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | MALLINCKRODT LLC (US) | 2016-08-31 | — | — | EP | claimed |
| US-9415044-B2 | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts | MALLINCKRODT LLC (US) | 2016-08-16 | — | — | US | claimed |
| US-20150164886-A9 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | MALLINCKRODT INC. (US) | 2015-06-18 | — | — | US | claimed |
| US-20150099773-A1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | VTESSE LLC | 2015-04-09 | — | — | US | claimed |
| US-20100035910-A1 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | MALLINCKRODT INC. (US) | 2010-02-11 | — | — | US | claimed |
| EP-2147920-A2 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | Mallinckrodt Inc. (US) | 2010-01-27 | — | — | EP | claimed |
| EP-2137189-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | Mallinckrodt Inc. (US) | 2009-12-30 | — | — | EP | claimed |
| WO-2008109156-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC. (US) | 2008-09-12 | — | — | WO | claimed |
| US-9527858-B2 | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers | MALLINCKRODT LLC (US) | 2016-12-27 | — | — | US | disclosed |
| US-9518062-B2 | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers | MALLINCKRODT LLC (US) | 2016-12-13 | — | — | US | disclosed |
| EP-2147920-B1 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | MALLINCKRODT LLC (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9415044-B2 | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts | MALLINCKRODT LLC (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150164886-A9 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | MALLINCKRODT INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-9040726-B2 | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts | MALLINCKRODT LLC (US) | 2015-05-26 | — | — | US | disclosed |
| US-20100035910-A1 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | MALLINCKRODT INC. (US) | 2010-02-11 | — | — | US | disclosed |
| EP-2147920-A2 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | Mallinckrodt Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| EP-2137189-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | Mallinckrodt Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008109156-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20030055297-A1 | An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation | ABBOTT LABORATORIES | 2003-03-20 | — | — | US | disclosed |
| WO-2002081441-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRROLIDINE NEURAMINIDASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035910-A1 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | RAN, RANBP1, NCLN | SLC1A3 1333/4885SLC1A2 1153/4885SLC1A1 1307/4885 |
| US-20030055297-A1 | An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation | NEU4, NEU2, NEU1 | SLC1A3 3877/4885SLC1A2 3989/4885SLC1A1 4021/4885 |
| US-20150099773-A1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | RAN, RANBP1, NCLN | SLC1A3 1333/4885SLC1A2 1153/4885SLC1A1 1307/4885 |
| US-20150164886-A9 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | RAN, RANBP1, NCLN | SLC1A3 1333/4885SLC1A2 1153/4885SLC1A1 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.